ERBB2 and glioblastoma: However, there is one clinical trial (NCT03383978) that is actively recruiting and aims to study the intracranial injection of NK-92/5.28.z cells in combination with intravenous ezabenlimab in patients with recurrent HER2+ glioblastoma [377].